MedPath

Efficacy of 448kilohertz Capacitive Resistive Monopolar Radiofrequency Stimulation in Chronic Shoulder Pain

Not Applicable
Conditions
Chronic Shoulder Pain
Interventions
Other: No intervention
Other: Sham comparator
Registration Number
NCT04245969
Lead Sponsor
University of Malaga
Brief Summary

448kilohertz capacitive resistive monopolar radiofrequency is a novel technique in physiotherapy and its usefulness and clinical relevance is still to be investigated. Current studies show promising results in different musculoskeletal disorders, however further studies with proper designs and conclusive findings are necessary.

Detailed Description

Shoulder pain is is one of the most common musculoskeletal disorders, presenting a high prevalence in primary care centers. Many factors have been proposed as the cause of pain, however it is still controversial and the same regarding the best treatment option.

Treatments throw different techniques have been investigated, showing a variety of results in terms of pain and sensitivity. However, the use of 448kilohertz capacitive resistive monopolar radiofrequency as the focus of the treatment is to be explored.

The hypothesis of the present project is that focus treatments on 448kilohertz capacitive resistive monopolar radiofrequency on the shoulder will produce better outcomes in terms of ultrasound assessment, strength, pain, sensitivity and range of movement, when compared to traditional methods used like manual therapy and/or exercise.

The stimulus will be carried out on the shoulder region (suprascapular, axillar, subscapular, long thoracic or pectoralis nerves) and the thoracic region. All interventions will be developed by the same examiner, who is a physiotherapist with 6 years of clinical experience.

The outcome measures will be electromyography and dynamometry to measure strength and muscular activity. The movements required to the patient will be shoulder flexion, abduction, adduction, and extension.

To quantify sensitivity, pain pressure thresholds will be measured throw an algometer placed on the coracoid process, on the lateral area of the shoulder (two centimeters below the acromion and on the acromioclavicular joint).

To measure the range of movement, a goniometer will be used for both glenohumeral and scapular rotations.

To measure quality of life and psychological factors several questionnaires will be asked (Pain catastrophizing scale, Pain vigilance and awareness questionnaire, Self-efficacy, SPADI, Tampa Scale-11, McGill)

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
30
Inclusion Criteria
  • To suffer from shoulder pain more than three months.
  • Men or women aged between 18 to 65 years;
  • Unilateral pain located in the anterior and/or lateral shoulder region;
  • 2 out of 3 positive clinical tests (Hawkins-Kennedy; Jobe; Neer);
  • Pain with normal activity ≥ 4/10 on a visual analogue scale;
  • Nontraumatic onset of shoulder pain.
Exclusion Criteria
  • History of significant shoulder trauma, such as fracture or ultrasonography-clinically suspected full thickness cuff tear, following the classification of Wiener and Seitz
  • Recent shoulder dislocation in the past two years
  • Systemic illnesses such as rheumatoid arthritis
  • Adhesive capsulitis of the shoulder
  • Shoulder pain originating from the neck or if there was a neurological impairment, osteoporosis, hemophilia and/or malignancies.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
No intervention groupNo interventionTo evaluate at the same time than the others groups but without being treated with 448 kilohertz Capacitive Resistive Monopolar Radiofrequency.
Placebo Monopolar Radiofrequency stimulusSham comparatorTo simulate the application of Monopolar Radiofrequency stimulus on the affected shoulder
Primary Outcome Measures
NameTimeMethod
Change from Baseline ultrasound imaging at 3 monthstime (t) 1(prior to treatment), t2 (immediately after the treatment), t3 (3 months later)

Tendon thickness

Secondary Outcome Measures
NameTimeMethod
Electromyographytime (t) 1(prior to treatment), t2 (immediately after the treatment), t3 (3 months later)

Electromyography of different shoulder muscles (deltoid, trapezius,serratus )will be measured.

Autonomic Symptom Profile questionnaire (ASP)time (t) 1(prior to treatment), t2 (immediately after the treatment), t3 (3 months later)

Measurement of Autonomic nervous system activity:

The Autonomic Symptom Profile (ASP) is a validated self-report questionnaire that comprehensively assesses autonomic symptoms across 11 subscales and yields a composite autonomic symptom score

Change from Baseline dynamometry at 3 monthstime (t) 1(prior to treatment), t2 (immediately after the treatment), t3 (3 months later)

Strength of different shoulder muscles (deltoid, trapezius,serratus )will be measured.

Change from baseline SPADI (Shoulder Pain And Disability Index) questionnaire at three monthstime (t) 1(prior to treatment), t2 (immediately after the treatment), t3 (3 months later)

The Shoulder Pain and Disability Index (SPADI) is a self-administered questionnaire that consists of two dimensions, one for pain and the other for functional activities.

Algometrytime (t) 1(prior to treatment), t2 (immediately after the treatment), t3 (3 months later)

Pain pressure thresholds of different shoulder muscles (deltoid, trapezius,serratus )will be measured

Heart rate variability (HRV)time (t) 1(prior to treatment), t2 (immediately after the treatment), t3 (3 months later)

Measurement of Autonomic nervous system activity:

Resting HRV provides quantitative information regarding cardiac autonomic tone.

Range of movementtime (t) 1(prior to treatment), t2 (immediately after the treatment), t3 (3 months later)

Measurement of mobility in different planes:

Active shoulder flexion and abduction will be measured with the patient seated, in the scapular plane and relative to the thorax. In addition, active external and internal rotation will be measured in neutral (shoulder in adduction), 30°, 60° and 90° of abducted position.

Catastrophizing Scale questionnairetime (t) 1(prior to treatment), t2 (immediately after the treatment), t3 (3 months later)

Assessment of the mechanisms by which catastrophizing impacts on pain experience.

© Copyright 2025. All Rights Reserved by MedPath